Systemic and Local Immunological Predictors of the Unfavorable Course of Breast Cancer
Keywords:
breast cancer, prognosis, tumor grade, immunological predictors, microRNA, lymph node metastasis, survival, tumor heterogeneityAbstract
Breast cancer remains one of the leading causes of morbidity and mortality among women worldwide, with prognosis determined not only by early detection but also by tumor biology. Despite advances in molecular classification, current approaches are insufficient to fully predict disease progression, as recurrence and unfavorable outcomes occur even in clinically favorable groups. This highlights a critical knowledge gap in identifying reliable, accessible prognostic markers that reflect tumor heterogeneity and guide individualized treatment. This study analyzes systemic and local immunological and morphological predictors of breast cancer progression using existing clinical, histological, and molecular data. Particular attention is given to tumor grade, lymph node involvement, tumor size, receptor status, and emerging genetic factors such as microRNA expression. Findings demonstrate that tumor malignancy grade is a strong independent predictor of recurrence and survival, often exceeding the prognostic value of tumor size. Additionally, lymph node status and disease stage remain significant determinants of outcomes, while younger patient age is associated with more aggressive disease forms and lower survival rates. The results confirm that a multifactorial approach combining classical and emerging biomarkers improves prognostic accuracy. The study implies that integrating immunological and morphological indicators into clinical decision making could enhance risk stratification and optimize therapeutic strategies, potentially reducing unnecessary chemotherapy and improving patient quality of life.
References
1. A. B. Abduraimov, K. A. Lesko, and S. N. Karpova, “Features of X ray and ultrasound diagnostics of breast mucosal cancer,” Malignant Tumors, no. 4, pp. 31–34, 2016.
2. A. S. Balkanov and N. N. Petrushkina, “Features of brain metastasis in patients with luminal subtype of breast cancer,” Almanac of Clinical Medicine, pp. 635–639, 2016.
3. N. N. Volchenko, O. V. Borisova, A. G. Ermolaeva, and V. Yu. Melnikova, “Cytological diagnosis of breast diseases based on trepan biopsies,” News of Clinical Cytology of Russia, vol. 22, no. 1, pp. 30–35, 2018.
4. L. A. Gordeeva, I. E. Loiko, E. N. Voronina et al., “Mutations in tumor suppressor genes and their relationship to phenotypic patterns of breast cancer in young women,” Human Ecological Genetics, vol. 16, no. 3, pp. 63–68, 2018.
5. E. M. Dobrenka, “The influence of body weight and age on the prognosis of breast cancer,” in Current Issues of Modern Medicine: Proc. Astrakhan State Medical Academy, vol. 37, pp. 259–260, 2008.
6. L. G. Zhukova, “Breast cancer with a triple negative phenotype in the Russian patient population: Clinical and morphological features,” Issues of Oncology, no. 2, pp. 189–194, 2015.
7. L. E. Zavalishina and G. A. Frank, “Morphological testing of HER2 status in breast cancer,” Russian Medical Journal, vol. 14, no. 24, pp. 1737–1739, 2006.
8. A. H. Ismagilov, N. G. Asnina, I. P. Moshurov, and G. A. Azarov, “Prediction of metastatic lesion of regional lymph nodes in patients with breast cancer,” Tumors of the Female Reproductive System, vol. 13, pp. 13–18, 2017.
9. A. D. Kaprin, V. V. Starinsky, and G. V. Petrova, Eds., Malignant Neoplasms in Russia in 2013. Moscow, Russia: Medicine, 2016.
10. A. V. Markovsky, N. N. Strambovskaya, and P. P. Tereshkov, “Molecular genetic and serum markers of folate metabolism disorders in patients with proliferative diseases and breast cancer,” Siberian Journal of Oncology, vol. 16, no. 2, pp. 50–55, 2017.
11. S. Osinsky and P. Vaupel, Microphysiology of Tumors. Kiev, Ukraine: Naukova Dumka, 2009.
12. D. A. Ryabchikov, I. K. Vorotnikov, N. A. Kozlov, and N. V. Chkhikvadze, “Androgen receptors as a prognostic factor in various morphological subtypes of breast cancer,” Siberian Journal of Oncology, vol. 16, no. 3, pp. 40–45, 2017.
13. V. V. Starinsky, A. D. Kaprin, and G. V. Petrova, Eds., Malignant Neoplasms in Russia in 2016. Moscow, Russia: Federal State University of the Herzen Institute of Medical Sciences, 2018.
14. A. A. Khisamov, O. O. Manuylova, and M. Yu. Byakhov et al., “Mechanisms of development and ways of overcoming endocrine resistance in breast cancer,” Malignant Tumors, no. 4, pp. 52–57, 2015.
15. M. Y. Cheburkaeva, N. B. Zakharova, V. E. Fedorov et al., “Diagnostic value of biomarkers in the prognosis of postoperative relapses and metastases in patients with breast cancer,” Saratov Scientific Medical Journal, vol. 3, no. 2, pp. 240–244, 2017.
16. I. A. Albalawi, R. Mir, and F. M. Abu Duhier, “Molecular evaluation of PROGINS mutation in progesterone receptor gene and its association with breast cancer susceptibility in Saudi Arabia,” Endocrine, Metabolic and Immune Disorders Drug Targets, 2019, doi: 10.2174/1871530319666191125153050.
